ES8705461A1 - Procedimiento para la obtencion de nuevos compuestos este- roides - Google Patents

Procedimiento para la obtencion de nuevos compuestos este- roides

Info

Publication number
ES8705461A1
ES8705461A1 ES544770A ES544770A ES8705461A1 ES 8705461 A1 ES8705461 A1 ES 8705461A1 ES 544770 A ES544770 A ES 544770A ES 544770 A ES544770 A ES 544770A ES 8705461 A1 ES8705461 A1 ES 8705461A1
Authority
ES
Spain
Prior art keywords
analogues
alpha
group
oriented
open ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES544770A
Other languages
English (en)
Other versions
ES544770A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8705461A1 publication Critical patent/ES8705461A1/es
Publication of ES544770A0 publication Critical patent/ES544770A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PROCEDIMIENTO PARA OBTENER NUEVOS COMPUESTOS DE ESTEROIDES. CONSISTE EN HACER REACCIONAR UN COMPUESTO DE FORMULA (II) CON METILURO DE DIMETILSULFONIO, EN BENCENO, A PRESION NORMAL Y ENTRE 0J Y EL PUNTO DE EBULLICION DE LA MEZCLA DE REACCION, PARA OBTENER UN COMPUESTO DE FORMULA (I) Y SUS SALES DE ADICION DE ACIDO, SIENDO: A-A, EL GRUPO CH2-CH2 O CHFCH; R1 Y R2 SON UN RESTO A O B; B-B, EL GRUPO CH2-CH2 O A O B ORIENTADO; X ES DOS ATOMOS DE H U OXO; E Y1 E Y2 FORMAN UN PUENTE OXIGENO, HIDROXILO O ALCOXI. TIENEN UTILIDAD COMO DIURETICOS.
ES544770A 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides Expired ES8705461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
ES8705461A1 true ES8705461A1 (es) 1987-05-01
ES544770A0 ES544770A0 (es) 1987-05-01

Family

ID=4223123

Family Applications (4)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Country Status (23)

Country Link
US (1) US4559332A (es)
EP (1) EP0122232B1 (es)
JP (1) JPS59231100A (es)
AR (4) AR241918A1 (es)
AT (1) ATE39256T1 (es)
AU (1) AU565017B2 (es)
CA (1) CA1220781A (es)
DD (2) DD233375A5 (es)
DE (2) DE3475622D1 (es)
DK (1) DK163988C (es)
ES (4) ES531517A0 (es)
FI (1) FI77669C (es)
GR (1) GR81834B (es)
HU (1) HU191406B (es)
IE (1) IE57541B1 (es)
IL (1) IL71504A (es)
LU (1) LU91072I2 (es)
NL (1) NL300144I2 (es)
NO (1) NO159800C (es)
NZ (1) NZ207826A (es)
PH (1) PH19997A (es)
PT (1) PT78413B (es)
ZA (1) ZA842710B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
US5248807A (en) * 1991-01-29 1993-09-28 Shionogi & Co., Ltd. Triterpene derivatives
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
PT831910E (pt) * 1995-06-07 2002-05-31 Searle & Co Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
EP1170299A3 (en) * 1995-12-11 2004-11-10 G.D. Searle & Co. Intermediates useful in the preparation of 9,11-epoxy steroids and methods for their production
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
DE69637140T2 (de) 1995-12-11 2008-04-10 G.D. Searle Llc, Chicago Verfahren zur herstellung einer epoxy-verbindung
DE69716116T2 (de) 1996-12-11 2003-09-04 Searle & Co VERFAHREN ZUR HERSTELLUNG VON 3-KETO-7alpha-ALKOXYCARBONYL- delta4,5-STEROIDEN SOWIE ZWISCHENPRODUKTE
US6887991B1 (en) 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
EP1223174A3 (en) * 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6368835B1 (en) * 1998-05-29 2002-04-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing a lactone using corynebacterium sp. NK-1 (FERM BP-6329)
CZ20011590A3 (cs) * 1998-11-06 2003-01-15 G. D. Searle & Co. Léčivo pro léčení kardiovaskulárních poruch a kompozice s obsahem inhibitoru enzymu konvertujícího angiotensin, antagonisty aldosteronu, kličkového diuretika a digoxinu
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
ES2203239T3 (es) 1998-12-23 2004-04-01 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de agentes secuestrantes de acidos biliares para indicaciones cardiovasculares.
IL143947A0 (en) * 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
JP2002533414A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
NZ512536A (en) 1998-12-23 2003-11-28 G Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
AU776664B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
JP2003516414A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション より高い溶解速度を示すエプレレノン結晶形
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
EP1175434A2 (en) * 1999-12-08 2002-01-30 Pharmacia Corporation Eplerenone crystalline form
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
CA2409437A1 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AU2001285318A1 (en) * 2000-08-28 2002-03-13 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
WO2002046386A2 (en) * 2000-10-30 2002-06-13 Pharmacia Corporation Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
CN100408099C (zh) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 含有嵌段共聚物的口服药物组合物
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
IL162475A0 (en) 2001-12-12 2005-11-20 Pharmacia Corp Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
KR20040091141A (ko) * 2002-03-18 2004-10-27 파마시아 코포레이션 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
MXPA04009039A (es) * 2002-03-18 2005-01-25 Pharmacia Corp Combinacion de un antagonista de los receptores de la aldosterona y un agente secuestrante de los acidos biliares.
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
EP1490390A2 (en) * 2002-03-22 2004-12-29 Pharmacia Corporation C-17 spirolactonization and 6,7 oxidation of steroids
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
DE60308388T2 (de) * 2002-08-16 2007-09-20 Pharmacia & Upjohn Co. Llc, Kalamazoo 5-Androsten-3beta-ol-Steroide und Verfahren für ihre Herstellung
TW200407150A (en) * 2002-11-06 2004-05-16 Upjohn Co Processes for preparing 7- carboxy substituted steroids
EP1562974B1 (en) * 2002-11-07 2007-02-21 Pharmacia & Upjohn Company LLC Processes for preparing c-7 substituted 5-androstenes
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
AR049479A1 (es) * 2004-03-22 2006-08-09 Pharmacia & Upjohn Co Llc Proceso mejorado para la preparacion de 9,11-epoxi esteroides
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
US20100086586A1 (en) * 2006-12-21 2010-04-08 Brett Antony Mooney Pharmaceutical Composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2533799B8 (en) * 2010-02-08 2019-12-25 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
US9562068B2 (en) 2014-10-17 2017-02-07 Industriale Chimica, S.R.L. Process for the preparation of 7 α-(methoxycarbonyl)-3-OXO-17alpha-pregn-4,9(11)-dien-21,17-carbolactone, a useful intermediate for the synthesis of molecules with pharmacological activity
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
DD251144A5 (de) 1987-11-04
DK189484A (da) 1984-10-14
ES8705459A1 (es) 1987-05-01
LU91072I2 (fr) 2004-04-07
DD233375A5 (de) 1986-02-26
AR242222A1 (es) 1993-03-31
ES544768A0 (es) 1987-05-01
AR241918A1 (es) 1993-01-29
AR242221A1 (es) 1993-03-31
ATE39256T1 (de) 1988-12-15
NZ207826A (en) 1986-07-11
NO159800B (no) 1988-10-31
IE840906L (en) 1984-10-13
FI841400A (fi) 1984-10-14
EP0122232B1 (de) 1988-12-14
DK189484D0 (da) 1984-04-12
IE57541B1 (en) 1992-10-07
FI77669B (fi) 1988-12-30
AU2685384A (en) 1984-10-18
JPH0212479B2 (es) 1990-03-20
PT78413B (en) 1986-08-22
DE3475622D1 (en) 1989-01-19
ES544770A0 (es) 1987-05-01
PT78413A (en) 1984-05-01
JPS59231100A (ja) 1984-12-25
NL300144I1 (nl) 2004-06-01
FI77669C (fi) 1989-04-10
IL71504A (en) 1987-07-31
DE122004000012I2 (de) 2006-06-08
NO841465L (no) 1984-10-15
DE122004000012I1 (de) 2012-05-16
NO159800C (no) 1989-02-08
ES544769A0 (es) 1987-05-01
PH19997A (en) 1986-08-28
AU565017B2 (en) 1987-09-03
NL300144I2 (nl) 2004-06-01
FI841400A0 (fi) 1984-04-09
HU191406B (en) 1987-02-27
ES8705460A1 (es) 1987-05-01
US4559332A (en) 1985-12-17
GR81834B (es) 1984-12-12
CA1220781A (en) 1987-04-21
ES8602846A1 (es) 1985-12-01
IL71504A0 (en) 1984-07-31
ES531517A0 (es) 1985-12-01
AR242223A1 (es) 1993-03-31
DK163988B (da) 1992-04-27
DK163988C (da) 1992-09-21
ZA842710B (en) 1984-11-28
EP0122232A1 (de) 1984-10-17

Similar Documents

Publication Publication Date Title
ES8705460A1 (es) Procedimiento para la obtencion de nuevos compuestos este- roides
HU9202615D0 (en) Method for producing new 1-acyl-piperidine derivatives
ES8401498A1 (es) Procedimiento de preparacion de nuevos derivados esteroides sustituidos en 11b.
MY103365A (en) 4-demethoxy-4-amino-anthracyclines
NZ312303A (en) Novel nor-pregnanes for inducing hypothalamic effects
KR910004653A (ko) 스테로이드 5-α-환원효소의 억제제로서의 7-케토 또는 히드록시 3,5-디엔 스테로이드
ES2003200A6 (es) Un procedimiento para la preparacion de esteroides aminoglicosidicos.
ES8605535A1 (es) Procedimiento para la preparacion de 6,6-etilen-15,16-meti- len-3-oxo-17&-pregn-4-en-21,17-carbolactonas
MY100512A (en) New 6-or 7-methlenandrosta-1, 4-diene-3, 17-dione derivatives and process for their preparation.
ES8707737A1 (es) Procedimiento para la obtencion de una 9 l 11 l epoxiesteroide
ES2003201A6 (es) Un procedimiento para la preparacion de esteroides aminoglicosidicos.
ES8106914A1 (es) Procedimiento para la preparacion de nuevos derivados de amino-14 esteroides.
ES2003198A6 (es) Un procedimiento para la preparacion de esteroides aminoglicosidicos.
DK420985A (da) Fremgangsmaade til fremstilling af pregnanderivater
IL154828A0 (en) 17alpha FLUOROALKYL STEROIDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS
BG99313A (en) 117-alkylketonesteroids as 5- -reductase inhibitors
GB1498239A (en) Quaternary salts of d-homosteroids
WILKINS et al. Jr., ROSEMBERG, E., and MIGEON, CJ (1951). J. clin. Endocrin., 11, 1. ZAFFARONI, A., HECHTER, O., and PINCUS, G.(1951). J. Amer. chem.
IE850128L (en) Guanidine derivatives
ES8200703A1 (es) Procedimiento para la preparacion de 1-hidroxi-esteroides
GB1469223A (en) Azidocarbonic acid esters of steroids
TW343976B (en) 17-substituted steroids useful in cancer treatment

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070122